What is Amoy Diagnostics Co., Ltd.'s (300685.SZ) StockRank?

MoatMap's StockRank for Amoy Diagnostics Co., Ltd. (300685.SZ) is 80/100, with a Buy signal. This is a composite score combining Quality (84), Value (42), and Momentum (40) factor ranks across MoatMap's 20,000+ stock universe.

Does Amoy Diagnostics Co., Ltd. have an economic moat?

Amoy Diagnostics Co., Ltd. (300685.SZ) has a Quality factor score of 84/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Amoy Diagnostics Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Amoy Diagnostics Co., Ltd. (300685.SZ) is Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Amoy Diagnostics Co., Ltd. in?

Amoy Diagnostics Co., Ltd. (300685.SZ) operates in the Healthcare sector, specifically the Diagnostics & Research industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300685.SZ

BUYREMOVE

Amoy Diagnostics Co., Ltd. · Healthcare · China · $1.2B · Avg Vol: $23M/d

StockRank

P/E (TTM)

19.2x

ROE

17.9%

D/E

0.1x

Dividend %

2.7%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Amoy Diagnostics is a high-quality molecular diagnostics company in China. While it has solid R&D, it does not fit our CDMO pricing power theme, which focuses on large-scale biologics manufacturing rather than diagnostic kits.

COMPANY DESCRIPTION

Amoy Diagnostics Co., Ltd. specializes in the development and manufacture of molecular diagnostic products, focusing on companion diagnostics for personalized cancer treatment. The company's competitive moat is established through its proprietary ADx-ARMS technology and extensive regulatory approvals, alongside strategic partnerships with global pharmaceutical giants. It is a leading domestic player in China's oncology precision medicine sector, benefiting from high technical and regulatory entry barriers.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	124M	154M	164M	177M	12.5%
EPS	0.10	0.10	0.09	0.13	10.7%
Shares	398M	399M	398M	392M	-1.7%
Debt	8M	8M	8M	16M	26.5%
Equity	222M	252M	272M	304M	11.1%
Op CF	22M	44M	51M	54M	34.8%
Inv CF	-6M	-49M	-11M	-34M	—
Fin CF	-18M	-3M	-24M	-15M	—

PRICE (1M)-15.1%

SMA 50SMA 200

$2.48

RSI (14)

12.1

52W High

$3.78

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

19.0%90.5

ROE

17.9%86.9

GP/Assets

41.3%80.3

Op. Margin

38.6%96.1

FCF/Assets

5.8%73.7

Piotroski

—83.4

Int. Cover

50.0x91.5

D/E Ratio

0.10x66.4

Current Ratio

15.14x92.7

Value

P/E (TTM)

19.2x59.1

EV/EBITDA

12.1x35.9

P/FCF

400.1x22.6

P/B

3.2x37.2

P/S

5.6x37.4

Div Yield

2.7%62.1

Momentum

52W High %

66%49.3

RS 6M

-32%39.3

SMA 50/200

0.94x45.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+12%28.6

Q Growth

-6%35.9

FUNDAMENTALS

Market Cap

$1.2B

P/E (Forward)

17.1x

Gross Margin

81.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300685.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300685.SZ	Amoy Diagnostics Co., Ltd.(you)	$1.2B	80	BUY
300244.SZ	Dian Diagnostics Group Co.,Ltd.	$1.6B	78	BUY
300406.SZ	Beijing Strong Biotechnologies,Inc.	$1.0B	86	STRONG BUY
6127.HK	Joinn Laboratories(China)Co.,Ltd.	$1.7B	77	BUY
603882.SS	Guangzhou Kingmed Diagnostics Group Co., Ltd.	$1.8B	67	BUY
9960.HK	Kindstar Globalgene Technology, Inc.	$139M	70	BUY
300463.SZ	Maccura Biotechnology Co.Ltd	$845M	33	SELL
2427.HK	Guanze Medical Information Industry (Holding) Co., Ltd.	$526M	42	HOLD
300676.SZ	BGI Genomics Co., Ltd.	$2.3B	37	HOLD
603108.SS	Shanghai Runda Medical Technology Co., Ltd.	$1.1B	21	SELL

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Amoy Diagnostics Co., Ltd. (300685.SZ) — Stock Score Summary

Amoy Diagnostics Co., Ltd. (300685.SZ) has a MoatMap StockRank of 80/100 based on Quality (84/100), Value (42/100), and Momentum (40/100) factor scores. The current signal is BUY. Amoy Diagnostics is a high-quality molecular diagnostics company in China. While it has solid R&D, it does not fit our CDMO pricing power theme, which focuses on large-scale biologics manufacturing rather than diagnostic kits.

Key Financial Metrics

Price	$2.48
Market Cap	$1.2B
P/E (TTM)	19.16
P/E (Forward)	17.05
Price/Book	3.21
Return on Equity	17.9%
Return on Invested Capital	19.0%
Debt/Equity	9.74
Gross Margin	81.5%
Operating Margin	38.6%
Revenue Growth	-4.3%
Dividend Yield	2.7%
Free Cash Flow	$3M

Amoy Diagnostics Co., Ltd. operates in the Diagnostics & Research industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Amoy Diagnostics Co., Ltd.’s (300685.SZ) StockRank?: MoatMap’s StockRank for Amoy Diagnostics Co., Ltd. (300685.SZ) is 80/100, with a Buy signal. It is a composite of Quality (84), Value (42), and Momentum (40) factor ranks across MoatMap’s 20,000+ stock universe.
Does Amoy Diagnostics Co., Ltd. have an economic moat?: Amoy Diagnostics Co., Ltd. (300685.SZ) has a Quality factor score of 84/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Amoy Diagnostics Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Amoy Diagnostics Co., Ltd. (300685.SZ) is Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Amoy Diagnostics Co., Ltd. in?: Amoy Diagnostics Co., Ltd. (300685.SZ) operates in the Healthcare sector, specifically the Diagnostics & Research industry (China).